Antheia, a pharmaceutical ingredient manufacturer, and Olon Group, a developer and manufacturer of active pharmaceutical ingredients (APIs) for CDMO and generic markets, announced an ongoing partnership to leverage Olon’s vast fermentation infrastructure to manufacture Antheia’s early products.
 
Antheia and Olon partnered in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since served as a CDMO for scaling Antheia’s biomanufacturing processes and producing its Biosynthetic KSMs (key starting materials) and APIs. In 2024 and beyond, Antheia will continue to partner with Olon for additional capacity to meet international demand for its first products, including thebaine.
 
“The third-party partners we work with are a huge part of our success, so finding the right CDMO to help bring our first products to industrial scale efficiently and rapidly was a critical decision early in our commercialization journey,” said Zack McGahey, COO of Antheia. “Olon is a well-respected CDMO of high-quality pharmaceutical products and a trusted partner to us as we continue our work together to ship our first products later this year and ultimately, transform essential medicine supply chains.”
 
With 5,000 cubic meters of fermentation capacity at its sites, Olon Biotech, a division of Olon Group, provides high-quality fermentation manufacturing services and is a globally licensed API manufacturer. Olon’s global infrastructure and industry expertise were instrumental to Antheia’s recent commercial milestones for its first product, thebaine.
 
“This successful partnership has yielded significant results and represents a promising future for pharma supply chains. Over the last five years, we have massively invested in our Biotech Centers, generating a significant increase in capacity and upgrading production processes for greater efficiency, and importantly, reducing the environmental impact of our production,” said Maurizio Sartorato, VP of Olon Biotech.